Skip to main content
Top
Published in: Journal of Translational Medicine 1/2021

Open Access 01-12-2021 | Research

Exogenous bacterial DnaK increases protein kinases activity in human cancer cell lines

Authors: Francesca Benedetti, Sabrina Curreli, Robert C. Gallo, Davide Zella

Published in: Journal of Translational Medicine | Issue 1/2021

Login to get access

Abstract

Background

Studies of molecular mechanisms underlying tumor cell signaling highlighted a critical role for kinases in carcinogenesis and cancer progression. To this regard, protein kinases regulates a number of critical cellular pathways by adding phosphate groups to specific substrates. For this reason, their involvement in the complex interactions between the human microbiota and cancer cells to determine therapy and tumor progression outcome is becoming increasingly relevant. Mycoplasmas are components of the normal human microbiota, and several species have also been associated to human diseases, including certain cancers. It is also important to note that Mycoplasmas and their proteins are a component of the common tumor microenvironment. In addition, several epidemiological, in vivo and in vitro studies indicate a close involvement of Mycoplasmas in cellular transformation and cancer progression.

Methods

In this study, we investigate the effect of exogenous Mycoplasma DnaK on kinases activity by treating in vitro four different eukaryotic cancer cell lines, namely lung and prostate cancer, colon adenocarcinoma, and neuroblastoma. Phosphorylation of kinases and specific substrates was measured at 20 and 60 min.

Results

Kinome analysis of our data indicates that Mycoplasma DnaK promotes the dysregulation of the activity of specific kinases and their substrates, with a known involvement in carcinogenesis and cancer progression.

Conclusions

Given the similarity in structure and amino acid composition of this protein with other bacterial DnaKs we provide a novel mechanism whereby components of the human microbiota and present in the tumor microenvironment are able to deregulate phosphorylation events occurring during carcinogenesis and cancer progression.
Literature
1.
go back to reference Roskoski R Jr. A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol Res. 2015;100:1–23.PubMedCrossRef Roskoski R Jr. A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol Res. 2015;100:1–23.PubMedCrossRef
2.
go back to reference Manning G, et al. The protein kinase complement of the human genome. Science. 2002;298(5600):1912–34.PubMedCrossRef Manning G, et al. The protein kinase complement of the human genome. Science. 2002;298(5600):1912–34.PubMedCrossRef
4.
go back to reference Leroux AE, Schulze JO, Biondi RM. AGC kinases, mechanisms of regulation and innovative drug development. Semin Cancer Biol. 2018;48:1–17.PubMedCrossRef Leroux AE, Schulze JO, Biondi RM. AGC kinases, mechanisms of regulation and innovative drug development. Semin Cancer Biol. 2018;48:1–17.PubMedCrossRef
5.
go back to reference Takemoto-Kimura S, et al. Calmodulin kinases: essential regulators in health and disease. J Neurochem. 2017;141(6):808–18.PubMedCrossRef Takemoto-Kimura S, et al. Calmodulin kinases: essential regulators in health and disease. J Neurochem. 2017;141(6):808–18.PubMedCrossRef
6.
go back to reference Cozza G, Pinna LA. Casein kinases as potential therapeutic targets. Expert Opin Ther Targets. 2016;20(3):319–40.PubMedCrossRef Cozza G, Pinna LA. Casein kinases as potential therapeutic targets. Expert Opin Ther Targets. 2016;20(3):319–40.PubMedCrossRef
7.
go back to reference Varjosalo M, et al. The protein interaction landscape of the human CMGC kinase group. Cell Rep. 2013;3(4):1306–20.PubMedCrossRef Varjosalo M, et al. The protein interaction landscape of the human CMGC kinase group. Cell Rep. 2013;3(4):1306–20.PubMedCrossRef
8.
go back to reference Miller CJ, et al. Comprehensive profiling of the STE20 kinase family defines features essential for selective substrate targeting and signaling output. PLoS Biol. 2019;17(3):e2006540.PubMedPubMedCentralCrossRef Miller CJ, et al. Comprehensive profiling of the STE20 kinase family defines features essential for selective substrate targeting and signaling output. PLoS Biol. 2019;17(3):e2006540.PubMedPubMedCentralCrossRef
9.
go back to reference Duong-Ly KC, Peterson JR. Chapter 2: The human kinome and kinase inhibition. In: Current protocols in pharmacology. New York: Wiley; 2013. p. Unit2.9. Duong-Ly KC, Peterson JR. Chapter 2: The human kinome and kinase inhibition. In: Current protocols in pharmacology. New York: Wiley; 2013. p. Unit2.9.
11.
go back to reference Kanev GK, et al. The landscape of atypical and eukaryotic protein kinases. Trends Pharmacol Sci. 2019;40(11):818–32.PubMedCrossRef Kanev GK, et al. The landscape of atypical and eukaryotic protein kinases. Trends Pharmacol Sci. 2019;40(11):818–32.PubMedCrossRef
13.
go back to reference Zhao Y, Wang X. PLK4: a promising target for cancer therapy. J Cancer Res Clin Oncol. 2019;145(10):2413–22.PubMedCrossRef Zhao Y, Wang X. PLK4: a promising target for cancer therapy. J Cancer Res Clin Oncol. 2019;145(10):2413–22.PubMedCrossRef
15.
go back to reference Lee BY, et al. FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther. 2015;146:132–49.PubMedCrossRef Lee BY, et al. FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther. 2015;146:132–49.PubMedCrossRef
16.
go back to reference Roskoski R Jr. Targeting ERK1/2 protein-serine/threonine kinases in human cancers. Pharmacol Res. 2019;142:151–68.PubMedCrossRef Roskoski R Jr. Targeting ERK1/2 protein-serine/threonine kinases in human cancers. Pharmacol Res. 2019;142:151–68.PubMedCrossRef
17.
go back to reference Kittler H, Tschandl P. Driver mutations in the mitogen-activated protein kinase pathway: the seeds of good and evil. Br J Dermatol. 2018;178(1):26–7.PubMedCrossRef Kittler H, Tschandl P. Driver mutations in the mitogen-activated protein kinase pathway: the seeds of good and evil. Br J Dermatol. 2018;178(1):26–7.PubMedCrossRef
18.
go back to reference Maurer G, Tarkowski B, Baccarini M. Raf kinases in cancer—roles and therapeutic opportunities. Oncogene. 2011;30(32):3477–88.PubMedCrossRef Maurer G, Tarkowski B, Baccarini M. Raf kinases in cancer—roles and therapeutic opportunities. Oncogene. 2011;30(32):3477–88.PubMedCrossRef
19.
go back to reference Pillai P, et al. Cancer kinases and its novel inhibitors: past, present and future challenges. Curr Drug Targets. 2015;16(11):1233–45.PubMedCrossRef Pillai P, et al. Cancer kinases and its novel inhibitors: past, present and future challenges. Curr Drug Targets. 2015;16(11):1233–45.PubMedCrossRef
21.
go back to reference Saylor PJ, Escudier B, Michaelson MD. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy. Clin Genitourin Cancer. 2012;10(2):77–83.PubMedCrossRef Saylor PJ, Escudier B, Michaelson MD. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy. Clin Genitourin Cancer. 2012;10(2):77–83.PubMedCrossRef
22.
go back to reference Asakawa H, et al. Chemosensitivity of anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma. Anticancer Res. 1997;17(4a):2757–62.PubMed Asakawa H, et al. Chemosensitivity of anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma. Anticancer Res. 1997;17(4a):2757–62.PubMed
23.
go back to reference Sugawara I, et al. Expression of multidrug resistance-associated protein (MRP) in thyroid cancers. Cancer Lett. 1995;95(1):135–8.PubMedCrossRef Sugawara I, et al. Expression of multidrug resistance-associated protein (MRP) in thyroid cancers. Cancer Lett. 1995;95(1):135–8.PubMedCrossRef
24.
go back to reference Wang SH, et al. Susceptibility of thyroid cancer cells to 7-hydroxystaurosporine-induced apoptosis correlates with Bcl-2 protein level. Thyroid. 2001;11(8):725–31.PubMedCrossRef Wang SH, et al. Susceptibility of thyroid cancer cells to 7-hydroxystaurosporine-induced apoptosis correlates with Bcl-2 protein level. Thyroid. 2001;11(8):725–31.PubMedCrossRef
25.
go back to reference Kawahito Y, et al. Mycoplasma fermentans glycolipid-antigen as a pathogen of rheumatoid arthritis. Biochem Biophys Res Commun. 2008;369(2):561–6.PubMedCrossRef Kawahito Y, et al. Mycoplasma fermentans glycolipid-antigen as a pathogen of rheumatoid arthritis. Biochem Biophys Res Commun. 2008;369(2):561–6.PubMedCrossRef
26.
go back to reference Gilroy CB, Keat A, Taylor-Robinson D. The prevalence of Mycoplasma fermentans in patients with inflammatory arthritides. Rheumatology. 2001;40(12):1355–8.PubMedCrossRef Gilroy CB, Keat A, Taylor-Robinson D. The prevalence of Mycoplasma fermentans in patients with inflammatory arthritides. Rheumatology. 2001;40(12):1355–8.PubMedCrossRef
28.
go back to reference Taylor-Robinson D, Furr PM. Models of infection due to mycoplasmas, including Mycoplasma fermentans, in the genital tract and other sites in mice. Clin Infect Dis. 1993;17(Suppl 1):S280–2.PubMedCrossRef Taylor-Robinson D, Furr PM. Models of infection due to mycoplasmas, including Mycoplasma fermentans, in the genital tract and other sites in mice. Clin Infect Dis. 1993;17(Suppl 1):S280–2.PubMedCrossRef
29.
go back to reference Tully JG, et al. A newly discovered mycoplasma in the human urogenital tract. Lancet. 1981;1(8233):1288–91.PubMedCrossRef Tully JG, et al. A newly discovered mycoplasma in the human urogenital tract. Lancet. 1981;1(8233):1288–91.PubMedCrossRef
30.
32.
go back to reference Reddel RR, et al. Development of tumorigenicity in simian virus 40-immortalized human bronchial epithelial cell lines. Cancer Res. 1993;53(5):985–91.PubMed Reddel RR, et al. Development of tumorigenicity in simian virus 40-immortalized human bronchial epithelial cell lines. Cancer Res. 1993;53(5):985–91.PubMed
33.
go back to reference Choi HS, et al. Detection of mycoplasma infection in circulating tumor cells in patients with hepatocellular carcinoma. Biochem Biophys Res Commun. 2014;446(2):620–5.PubMedCrossRef Choi HS, et al. Detection of mycoplasma infection in circulating tumor cells in patients with hepatocellular carcinoma. Biochem Biophys Res Commun. 2014;446(2):620–5.PubMedCrossRef
34.
go back to reference Patil S, Rao RS, Raj AT. Role of Mycoplasma in the initiation and progression of oral cancer. J Int Oral Health. 2015;7(7):i–ii.PubMedPubMedCentral Patil S, Rao RS, Raj AT. Role of Mycoplasma in the initiation and progression of oral cancer. J Int Oral Health. 2015;7(7):i–ii.PubMedPubMedCentral
37.
go back to reference Zhang S, et al. Mycoplasma fermentans infection promotes immortalization of human peripheral blood mononuclear cells in culture. Blood. 2004;104(13):4252–9.PubMedCrossRef Zhang S, et al. Mycoplasma fermentans infection promotes immortalization of human peripheral blood mononuclear cells in culture. Blood. 2004;104(13):4252–9.PubMedCrossRef
38.
39.
go back to reference Zella D, et al. Mycoplasma promotes malignant transformation in vivo, and its DnaK, a bacterial chaperone protein, has broad oncogenic properties. Proc Natl Acad Sci. 2018;115(51):E12005–14.PubMedCrossRefPubMedCentral Zella D, et al. Mycoplasma promotes malignant transformation in vivo, and its DnaK, a bacterial chaperone protein, has broad oncogenic properties. Proc Natl Acad Sci. 2018;115(51):E12005–14.PubMedCrossRefPubMedCentral
41.
go back to reference Kim MK, et al. Mycoplasma infection promotes tumor progression via interaction of the mycoplasmal protein p37 and epithelial cell adhesion molecule in hepatocellular carcinoma. Cancer Lett. 2019;454:44–52.PubMedCrossRef Kim MK, et al. Mycoplasma infection promotes tumor progression via interaction of the mycoplasmal protein p37 and epithelial cell adhesion molecule in hepatocellular carcinoma. Cancer Lett. 2019;454:44–52.PubMedCrossRef
44.
go back to reference Hagemann L, et al. The surface-displayed chaperones GroEL and DnaK of Mycoplasma pneumoniae interact with human plasminogen and components of the extracellular matrix. Pathog Dis. 2017;75(3):ftx017.CrossRef Hagemann L, et al. The surface-displayed chaperones GroEL and DnaK of Mycoplasma pneumoniae interact with human plasminogen and components of the extracellular matrix. Pathog Dis. 2017;75(3):ftx017.CrossRef
46.
go back to reference Henderson B, Martin A. Bacterial virulence in the moonlight: multitasking bacterial moonlighting proteins are virulence determinants in infectious disease. Infect Immun. 2011;79(9):3476–91.PubMedPubMedCentralCrossRef Henderson B, Martin A. Bacterial virulence in the moonlight: multitasking bacterial moonlighting proteins are virulence determinants in infectious disease. Infect Immun. 2011;79(9):3476–91.PubMedPubMedCentralCrossRef
47.
go back to reference Henderson B. An overview of protein moonlighting in bacterial infection. Biochem Soc Trans. 2014;42(6):1720–7.PubMedCrossRef Henderson B. An overview of protein moonlighting in bacterial infection. Biochem Soc Trans. 2014;42(6):1720–7.PubMedCrossRef
48.
go back to reference Lopes FM, et al. Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies. Brain Res. 2010;1337:85–94.CrossRefPubMed Lopes FM, et al. Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies. Brain Res. 2010;1337:85–94.CrossRefPubMed
49.
go back to reference Eid S, et al. KinMap: a web-based tool for interactive navigation through human kinome data. BMC Bioinform. 2017;18(1):16.CrossRef Eid S, et al. KinMap: a web-based tool for interactive navigation through human kinome data. BMC Bioinform. 2017;18(1):16.CrossRef
51.
go back to reference Oda K, et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell. 2000;102(6):849–62.PubMedCrossRef Oda K, et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell. 2000;102(6):849–62.PubMedCrossRef
52.
54.
go back to reference Nascimento EBM, et al. Insulin-mediated phosphorylation of the proline-rich Akt substrate PRAS40 is impaired in insulin target tissues of high-fat diet-fed rats. Diabetes. 2006;55(12):3221.PubMedCrossRef Nascimento EBM, et al. Insulin-mediated phosphorylation of the proline-rich Akt substrate PRAS40 is impaired in insulin target tissues of high-fat diet-fed rats. Diabetes. 2006;55(12):3221.PubMedCrossRef
55.
go back to reference Wiza C, et al. Over-expression of PRAS40 enhances insulin sensitivity in skeletal muscle. Arch Physiol Biochem. 2014;120(2):64–72.PubMedCrossRef Wiza C, et al. Over-expression of PRAS40 enhances insulin sensitivity in skeletal muscle. Arch Physiol Biochem. 2014;120(2):64–72.PubMedCrossRef
56.
go back to reference Wanyeon K, et al. PIM1-activated PRAS40 regulates radioresistance in non-small cell lung cancer cells through interplay with FOXO3a, 14-3-3 and protein phosphatases. Radiat Res. 2011;176(5):539–52.CrossRef Wanyeon K, et al. PIM1-activated PRAS40 regulates radioresistance in non-small cell lung cancer cells through interplay with FOXO3a, 14-3-3 and protein phosphatases. Radiat Res. 2011;176(5):539–52.CrossRef
57.
go back to reference Huang L, et al. PRAS40 is a functionally critical target for EWS repression in Ewing sarcoma. Can Res. 2012;72(5):1260.CrossRef Huang L, et al. PRAS40 is a functionally critical target for EWS repression in Ewing sarcoma. Can Res. 2012;72(5):1260.CrossRef
58.
go back to reference Yuan K, et al. Phospho-PRAS40Thr246 predicts trastuzumab response in patients with HER2-positive metastatic breast cancer. Oncol Lett. 2015;9(2):785–9.PubMedCrossRef Yuan K, et al. Phospho-PRAS40Thr246 predicts trastuzumab response in patients with HER2-positive metastatic breast cancer. Oncol Lett. 2015;9(2):785–9.PubMedCrossRef
59.
go back to reference Hong X, et al. STAT5a-targeting miRNA enhances chemosensitivity to cisplatin and 5-fluorouracil in human colorectal cancer cells. Mol Med Rep. 2012;5(5):1215–9.PubMed Hong X, et al. STAT5a-targeting miRNA enhances chemosensitivity to cisplatin and 5-fluorouracil in human colorectal cancer cells. Mol Med Rep. 2012;5(5):1215–9.PubMed
60.
go back to reference Kapoor M, et al. Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation. Oncogene. 2000;19(3):358–64.PubMedCrossRef Kapoor M, et al. Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation. Oncogene. 2000;19(3):358–64.PubMedCrossRef
61.
go back to reference Shieh SY, et al. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 1997;91(3):325–34.PubMedCrossRef Shieh SY, et al. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 1997;91(3):325–34.PubMedCrossRef
62.
go back to reference Zhang Y, Xiong Y. A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation. Science. 2001;292(5523):1910–5.PubMedCrossRef Zhang Y, Xiong Y. A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation. Science. 2001;292(5523):1910–5.PubMedCrossRef
63.
go back to reference Chandra D, Choy G, Tang DG. Cytosolic accumulation of HSP60 during apoptosis with or without apparent mitochondrial release: evidence that its pro-apoptotic or pro-survival functions involve differential interactions with caspase-3. J Biol Chem. 2007;282(43):31289–301.PubMedCrossRef Chandra D, Choy G, Tang DG. Cytosolic accumulation of HSP60 during apoptosis with or without apparent mitochondrial release: evidence that its pro-apoptotic or pro-survival functions involve differential interactions with caspase-3. J Biol Chem. 2007;282(43):31289–301.PubMedCrossRef
64.
go back to reference Campanella C, et al. Upon oxidative stress, the antiapoptotic Hsp60/procaspase-3 complex persists in mucoepidermoid carcinoma cells. Eur J Histochem. 2008;52(4):221–8.PubMedCrossRef Campanella C, et al. Upon oxidative stress, the antiapoptotic Hsp60/procaspase-3 complex persists in mucoepidermoid carcinoma cells. Eur J Histochem. 2008;52(4):221–8.PubMedCrossRef
65.
67.
go back to reference Connelly L, et al. Biphasic regulation of NF-kappa B activity underlies the pro- and anti-inflammatory actions of nitric oxide. J Immunol. 2001;166(6):3873–81.PubMedCrossRef Connelly L, et al. Biphasic regulation of NF-kappa B activity underlies the pro- and anti-inflammatory actions of nitric oxide. J Immunol. 2001;166(6):3873–81.PubMedCrossRef
68.
go back to reference Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 2008;8(4):253–67.PubMedCrossRef Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 2008;8(4):253–67.PubMedCrossRef
70.
go back to reference Gamero AM, et al. STAT2 contributes to promotion of colorectal and skin carcinogenesis. Cancer Prev Res. 2010;3(4):495–504.CrossRef Gamero AM, et al. STAT2 contributes to promotion of colorectal and skin carcinogenesis. Cancer Prev Res. 2010;3(4):495–504.CrossRef
72.
go back to reference Benedetti F, Curreli S, Zella D. Mycoplasmas–host interaction: mechanisms of inflammation and association with cellular transformation. Microorganisms. 2020;8(9):1351.PubMedCentralCrossRef Benedetti F, Curreli S, Zella D. Mycoplasmas–host interaction: mechanisms of inflammation and association with cellular transformation. Microorganisms. 2020;8(9):1351.PubMedCentralCrossRef
76.
go back to reference Shipley MM, Mangold CA, Szpara ML. Differentiation of the SH-SY5Y human neuroblastoma cell line. J Vis Exp. 2016;108:53193. Shipley MM, Mangold CA, Szpara ML. Differentiation of the SH-SY5Y human neuroblastoma cell line. J Vis Exp. 2016;108:53193.
77.
go back to reference Teppola H, et al. Morphological differentiation towards neuronal phenotype of SH-SY5Y neuroblastoma cells by estradiol, retinoic acid and cholesterol. Neurochem Res. 2016;41(4):731–47.PubMedCrossRef Teppola H, et al. Morphological differentiation towards neuronal phenotype of SH-SY5Y neuroblastoma cells by estradiol, retinoic acid and cholesterol. Neurochem Res. 2016;41(4):731–47.PubMedCrossRef
78.
go back to reference Korecka JA, et al. Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS ONE. 2013;8(5):e63862–e63862.PubMedPubMedCentralCrossRef Korecka JA, et al. Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS ONE. 2013;8(5):e63862–e63862.PubMedPubMedCentralCrossRef
79.
go back to reference Dwane S, Durack E, Kiely PA. Optimising parameters for the differentiation of SH-SY5Y cells to study cell adhesion and cell migration. BMC Res Notes. 2013;6:366–366.PubMedPubMedCentralCrossRef Dwane S, Durack E, Kiely PA. Optimising parameters for the differentiation of SH-SY5Y cells to study cell adhesion and cell migration. BMC Res Notes. 2013;6:366–366.PubMedPubMedCentralCrossRef
80.
go back to reference Martini S, et al. PKCε controls mitotic progression by regulating centrosome migration and mitotic spindle assembly. Mol Cancer Res. 2018;16(1):3–15.PubMedCrossRef Martini S, et al. PKCε controls mitotic progression by regulating centrosome migration and mitotic spindle assembly. Mol Cancer Res. 2018;16(1):3–15.PubMedCrossRef
81.
go back to reference Isakov N. Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression. Semin Cancer Biol. 2018;48:36–52.PubMedCrossRef Isakov N. Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression. Semin Cancer Biol. 2018;48:36–52.PubMedCrossRef
82.
Metadata
Title
Exogenous bacterial DnaK increases protein kinases activity in human cancer cell lines
Authors
Francesca Benedetti
Sabrina Curreli
Robert C. Gallo
Davide Zella
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2021
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-021-02734-4

Other articles of this Issue 1/2021

Journal of Translational Medicine 1/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.